International C diff Awareness Conference and Health EXPO

Dr. Nicola Petrosillo discusses treating C difficile infection and maintaining antimicrobial stewardship during the height of the COVID-19 pandemic in Italy.

Results on this investigational antibiotic in its phase 2A study were presented at the C Diff. Conference today.

Presentation highlights from the second and final day of the 9th Annual International C. diff Conference & Health Expo.

Dr. Tamás Haidegger talks about his work to develop an AI-based scanner that tracks hand hygiene to prevent C difficile and other infections.

At the C Diff Foundation Conference, promising investigational modalities and therapies, as well as better treatment approaches are all being discussed in hopes of some real inroads being made in this field in the near future.

Although no longer indicated as a first-line therapy, metronidazole still has therapeutic benefits and can serve patients in certain settings and circumstances.

Highlights from some of this afternoon's presenters at the 9th Annual International C diff Conference & Health Expo.

Highlights from the morning session of the C Diff Foundation Conference included data about Pfizer's investigational vaccine, insights about Seres Therapeutics microbiome therapeutic, and a look at CDI incidence rates around COVID-19.

Curtis Donskey, MD, discussed his efforts to encourage C. diff patients and providers to do their part to reduce infection and reinoculation.

The development of these programs are being looked at for private practices in the community settings to try to create better prescribing practices and avoid the potential progression to health care associated infections.

The organization is hosting its 9th Annual International C Diff Conference and Health EXPO on Thursday and Friday this week. The conference is virtual and free to the public.

Secondary analyses indicate that bezlotoxumab is more effective in reducing C diff recurrence in patients with pre-specified risk factors.

Sahil Khanna, MBBS, MS, discusses the efficacy of fecal transplants and new investigational candidates that are being evaluated in clinical trials.

Maureen Spencer, RN, M.Ed., discusses how rapid molecular diagnostics are changing the treatment timeline for sepsis and Clostridium difficile (C diff).

Glenn Tillotson, PhD discusses the development of new antibiotics and therapies for C diff during an era when antibiotic resistance is a serious global health threat.

Edmund A. Hooker, MD, DrPH, discussed the gaps in disinfection in the hospital and how hospital beds can be properly sanitized to prevent the spread healthcare-associatedted infections.